[1]彭艳艳,李红玲△,张旭霞,等.89SrCl2治疗多发性骨转移92例对患者疼痛、体能状况及血常规影响研究*[J].陕西医学杂志,2018,(12):1556-1558.
　Peng Yanyan,Li Hongling,Zhang Xuxia,et al.The effect of 89SrCl2 on pain, physical status and blood routine in 92 patients with bone metastases[J].,2018,(12):1556-1558.
点击复制

89SrCl2治疗多发性骨转移92例对患者疼痛、体能状况及血常规影响研究*
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2018年12期
页码:
1556-1558
栏目:
临床研究
出版日期:
2018-12-31

文章信息/Info

Title:
The effect of 89SrCl2 on pain, physical status and blood routine in 92 patients with bone metastases
文章编号:
DOI:10.3969/j.issn.1000-7377.2018.12.012
作者:
彭艳艳; 李红玲△; 张旭霞; 张玲芳; 杨 静; 刘 乐; 邰宵辉
甘肃省人民医院肿瘤内科（兰州 730000）
Author(s):
Peng Yanyan;  Li Hongling;  Zhang Xuxia;  et al.
Gansu Provincial Hospital（ Lanzhou 730000）
关键词:
骨肿瘤/治疗 锶放射性同位素/治疗应用 癌性疼痛/治疗 体质 肿廇转移 血细胞计数
Keywords:
Key words Bone neoplasms/therapy Strontium Radioisotopes/therapeutic uses Cancer pain/therapy Neoplasm metastasis Body com Stitution Blood cell count
分类号:
R738.1
文献标志码:
A
摘要:
摘 要 目的：分析89SrCl2治疗对有化疗史及无化疗史的多发性骨转移癌患者疼痛、体能状况及血常规的影响。方法：将92例有89SrCl2治疗史的多发性骨转移癌患者根据有无化疗史分为有化疗史组及无化疗史组。对比两组患者89SrCl2治疗前后的疼痛评分及体能状况、治疗后骨髓抑制程度及时间。结果：有化疗史及无化疗组的患者分别使用89SrCl2后疼痛及体能状况均得到改善，前后对比差异具有统计学意义（P<0.05）；有化疗史组及无化疗史组患者疼痛缓解率分别为82.0%（41/50例）、81.0%（34/42例）。有化疗史组较无化疗史使用89SrCl2后发生Ⅲ度及以上骨髓抑制的比例增加，抑制时间相对延长，差异无统计学意义（P>0.05）。结论：89SrCl2治疗对于多发性骨转移癌患者在减轻疼痛及改善体能状况方面安全、有效；对于有多疗程化疗史的患者使用89SrCl2后发生骨髓抑制的风险增加，故应慎重选择治疗时机。
Abstract:
Abstracts Objective：Analyze the effects of 89SrCl2 on the pain, physical status and blood routine of patients with multiple bone metastases with chemotherapy history group and no chemotherapy history group. Methods：92 patients with multiple bone metastases were divided into chemotherapy history group and no chemotherapy history group.The NRS、KPS and Blood routinewere compared between the 2 groups before and after the treatment of 89SrCl2. Results: The NRS and KPS of the 2 groups were observed before and after treatment, and the degree and time of bone marrow suppression after treatment were observed. The pain and physical condition of patients with chemotherapy and without chemotherapy after used 89SrCl2 were improved, with statistical significance after comparing the difference (P<0.05); Chemotherapy history group and no chemotherapy history group the pain remission rate was 82% (41/50 cases) and 81% (34 /42 cases). In the group with history of chemotherapy, the proportion of myelosuppression with III degree and above increased after the use of 89SrCl2in the group without chemotherapy. The inhibition time was longer, but the difference was not statistically significant (P>0.05). Conclusion：89SrCl2 for multiple bone metastasis in the patients to relieve pain and improve the physical condition of safe and effective; for a course of chemotherapy in patients with a history of 89SrCl2, so the treatment should be careful.

参考文献/References:


[1] 蒋宁一.放射性核素治疗骨转移癌的研究进展 [J].同位素, 2001,14 (2): 107-111
[2] 殷铁军,鲜于志群,胡长耀. 89Sr治疗骨转移癌疼痛研究[J].肿瘤防治研究,2003,(3):233-235.
[3] 石远凯，孙 燕.临床肿瘤内科手册[M].北京:人民卫生出版社,2016:96-97.
[4] 中国抗癌协会癌症康复与姑息治疗专业委员会，中国抗癌协会临床肿瘤学协作专业委员会.恶性肿瘤骨转移及骨相关疾病床诊疗专家共识(2014)[M].北京: 北京大学医学出版社,2014:151-158.
[5] 于世英.恶性肿瘤骨转移临床诊断与治疗总论[M].北京:中国协和医科大学出版社,2014:271-279.
[6] Berebsib JR ,Hillner BE,Kyle RA,et al. The role of bisphosphonates in multiple myeloma [J].J Clin Oncol,2002,20:3719-3736.
[7] 黄 诚，张建国，胡 斌，等.153Sm-EDTMP联合唑来磷酸治疗前列腺癌骨转移［J］.陕西医学杂志,2009，38（2）：213-214.
[8] Zenda S,Nakagami Y,Toshima M,et al. Strontium-89(Sr-89)chloride in the treatment of various cancer patients with multiple bone metastases [J].Int J Clin Oncol，2014，19(4):739-743.
[9] 中华人民共和国卫生部医政司.核医学诊断和治疗规范[M].北京:科学出版社 ,1997：134-136. 〖ZK)〗
[10] Wang JQ，Gao CX，Yin H，等 .89Sr 及联合局部放疗治疗多发骨转移癌的疗效观察［J］.中德临床肿瘤学杂志：英文版,2010,9:536-538.
[11] Finlay IG，Mason MD，Shelley M.Ｒadioisotopes for the palliation of metastatic bone cancer:a systematic review［J］. The Lancet Oncology，2005，6(6):392-400.
[12] 白 侠,王雪梅,张 桃,等. 89SrCl 2 治疗多发性骨转移癌的疗效分析 [J].内蒙古医科大学学报,2013，35(6):423-424.
[13] 张惠玲,张宏伟,徐黎明.89Sr内照射治疗骨转移癌的疗效观察 [J].中国肿瘤临床与康复,2016，23（10）：1218-1219.
[14] Windsor PM. Predictors of response to strontium-89 (Metastron R)in skeletal metastases from prostate cancer: Report of a single centre’s 10-year experience［J］. Clinical Oncology,2001,13:219-227.

备注/Memo

备注/Memo:
*甘肃省自然科学基金资助项目(17JR5RA037)
更新日期/Last Update: 2019-01-21